Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market
Genmab's updated Phase 2 data for petosemtamab, an EGFR x LGR5 bispecific antibody, showed confirmed and unconfirmed ORRs of 75% in first-line and 67% in second-line metastatic colorectal cancer, with 81% ORR in first-line left-sided tumors. The longer follow-up confirmed most previously unconfirmed responses, supporting Genmab's ongoing global Phase 3 development program; findings were presented at the ESMO Congress 2026.
Key figures
- Drug Name
- petosemtamab
- Phase Of Trial
- Phase 2
- Orr 1l
- 75%
- Orr 2l
- 67%
- Orr 1l left sided
- 81%
- Median followup 1l months
- 5.9
- Median followup 2l months
- 7.1
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.